Friends of Cancer Research Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

WASHINGTON--The national cancer community has joined together to create a nonprofit organization, the Friends of Cancer Research, to commemorate the 25th anniversary of the National Cancer Act through a public awareness and education campaign on the importance of cancer research.

WASHINGTON--The national cancer community has joined togetherto create a nonprofit organization, the Friends of Cancer Research,to commemorate the 25th anniversary of the National Cancer Actthrough a public awareness and education campaign on the importanceof cancer research.

The Friends board includes members of the groups most active inthe fight against cancer, including the National Cancer AdvisoryBoard, National Coalition for Cancer Survivorship, Presidents'Cancer Panel, ASCO, AACR, National Alliance of Breast Cancer Organizations,Oncology Nursing Society, National Coalition for Cancer Research,American Cancer Society, and a number of prominent US cancer centers.

The campaign will include events and public forums at which RichardKlausner, MD, director of the National Cancer Institute, and othersenior officials will report to the American people on the stateof cancer research. These events will also provide an opportunityfor the cancer community and other interested parties to identifytheir most important research priorities for the coming years.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content